President Donald Trump has taken credit for a decline in U.S. prescription drug prices. In July, prices reportedly fell 0.8%, and they have decreased by 3.1% over the past year. The White House attributes this to Trump’s ‘most favored nation’ drug deals and the TrumpRx website aimed at providing ‘real relief to American families.’
However, drug pricing experts argue the situation is more complex. They highlight other influential elements, such as legislation from President Joe Biden’s tenure. This law enables Medicare to negotiate drug costs with pharmaceutical companies, a significant factor in recent price shifts. Furthermore, new generic and biosimilar drugs have hit the market, increasing competition and reducing brand-name drug prices.
It’s important to note that the prescription drug price index from the Labor Department measures what pharmacies are paid, not consumer payments. Juliette Cubanski from KFF explains this makes it difficult to attribute the price drop to a single policy change.
Factors Influencing Drug Price Changes
Experts say both competition and policy changes impact prescription drug prices. Dr. Benjamin Rome of Harvard Medical School notes that when drugs face generic competition, prices drop. For instance, biosimilar drugs for autoimmune conditions similar to Humira have entered the market, lowering costs for these treatments. Drug Stelara also saw price reductions due to market competition, as highlighted by Vanderbilt University’s Stacie Dusetzina.
Federal policies from the Biden era likely contributed, especially the 2022 Inflation Reduction Act. This act allowed Medicare to negotiate drug prices, starting with ten high-selling drugs in January. This likely influenced overall price trends.
The Trump administration supports these negotiations and projects further savings.
Assessing the Impact of Trump’s Policies
Trump credits ‘most favored nation’ deals for price reductions. However, experts indicate the effects remain unclear, given that the contracts and models for these deals haven’t fully taken effect. Dusetzina believes current prices relate more to the Inflation Reduction Act and Medicare negotiation programs than to other policies.
TrumpRx is praised for improving price transparency and offering drug price deals. Yet, it remains unknown how widely the service is used. Some featured brand-name drugs are cheaper with insurance or have generic alternatives. Despite claimed savings of $700 million, the method for calculating such savings is questioned by figures like Sen. Elizabeth Warren.
Consumer Costs Remain High
Despite a reported drop in drug prices, many consumers still face high costs. The Labor Department’s index measures pharmacy payments, not direct consumer outlays. Patient costs vary based on insurance coverage and drug availability. Higher health spending and policy changes have also led to a rise in insurance premiums and out-of-pocket costs, potentially offsetting drug price reductions.
According to Dr. Rome, the consumer price index (CPI) may not fully capture healthcare cost experiences, unlike goods such as groceries and gas.